Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up rollover study of nivolumab across tumor types
NL-OMON50106Phase 2Withdrawn
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab in cancer (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Incidence of adverse events. Planned start Mar 2020; status: withdrawn.
02
Drugs
03
Conditions
cancer
Beyond the preview
Go deeper on NL-OMON50106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50106.